Warfarin versus DOACs in the prevention of thromboembolic stroke in patients with Afib. : Warfarin versus DOACs in the prevention of thromboembolic stroke in patients with Afib.

Allen Szabon

doi:10.5203/jcanpa.v3i7.900

Authors

PA Allen Szabon CD, DMSc, MPAS, CCPA Physician Assistant CCPA, Alberta Health Services, Physical Medicine and Rehabilitation

DOI:

https://doi.org/10.5203/jcanpa.v3i7.900

Keywords:

A search was conducted with search terms of “Oral Anticoagulants”, “Anticoagulants”, “Direct Oral Anticoagulants”, “New Oral Anticoagulants”, “Warfarin”, and “secondary prevention of non-valvular Afib”, “Afib”, “Stroke prevention” and “Stroke”.

Abstract

ABSTRACT

Preventing thromboembolic (TE) events “such as stroke” is an important part of managing patients with non-valvular atrial fibrillation (Afib). Over the last 50 years, oral anticoagulant treatment with the Vitamin K Antagonist (VKA) warfarin has played a crucial role in the secondary prevention of stroke for patients with Afib. Direct oral anticoagulant (DOACs), and their dominance over warfarin has arrived for treatment of Afib in the context of stroke prevention and research indicates DOACs are, for the most part, superior to warfarin in the secondary prevention of stroke in patients with non-valvular Afib. But what does the evidence tell us about risk versus benefits? The purpose of this review of literature is to conduct a systematic review of the advantages and disadvantages of DOACs, namely dabigatran, rivaroxaban, apixaban and edoxaban compared with warfarin in patients with (non-valvular) Afib.

In general, this review demonstrates the advantages of DOACs compared with warfarin including, DOACs are associated with lower rates of life-threatening and intracranial bleeding, DOACs have a rapid onset with peak effect within a few hours, they have predictable dose responses, thus eliminating the need for routine monitoring; and they have few, if any, important food or drug interactions, thus simplifying management. The findings of this systematic literature review suggest that in the secondary prevention of stroke in patients with non-valvular Afib, DOACs, demonstrate a significant advantage and enhanced safety profile over warfarin in reducing the risk of thromboembolic stroke compared with warfarin. As such, DOACs should be considered first-line therapy in the secondary prevention of stroke in patients with non-valvular Afib.

References

WIGLE P et al. American Family Physician. Anticoagulation: Updated Guidelines for Outpatient Management. 1;100(7):426-434. https://www.aafp.org/afp/2019/1001/p426.html [Published April 15, 2013. Updated Oct 1, 2019]. Accessed February 23, 2020.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857–867. pmid:17577005 View ArticlePubMed/NCBIGoogle Scholar

Zulkifly H, Lip G, and Lane D. PubMed. Epidemiology of atrial fibrillation. 2018 Mar;72(3):e13070. doi: 10.1111/ijcp.13070. [Epub 2018 Mar 1].

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 study. Circulation. 2014;129:837–47. [PMC free article] [PubMed] [Google Scholar]

How unseen links are putting us at risk. 2019 Report on Heart, Stroke and Vascular Cognitive Impairment. https://www.heartandstroke.ca/-/media/pdf-files/canada/2019-report/heartandstrokereport2019.ashx Published 2019.

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update: A report from the American Heart Association. Circulation. 2014;129:e28–92. [PMC free article] [PubMed] [Google Scholar]

Canadian stroke best practices. Anticoagulation for Individuals with Stroke and Atrial Fibrillation, section 7. https://www.strokebestpractices.ca/recommendations/secondary-prevention-of-stroke/anticoagulation-for-individuals-with-stroke-and-atrials-fibrillation [Updated October 2017].

Granger CB, Alexander JH, McMurray JJ, et al. “Apixaban versus warfarin in patients with atrial fibrillation.” N Engl J Med 2011; 365: 981–92. (ARISTOTLE).

Connolly SJ, Ezekowitz MD, Yusuf S, et al. “Dabigatran versus warfarin in patients with atrial fibrillation.” N Engl J Med 2009; 361: 1139–51. (RELY).

Patel MR, Mahaff ey KW, Garg J, et al. “Rivaroxaban versus warfarin in nonvalvular atrial fibrilla-tion.” N Engl J Med 2011; 365: 883–91. (ROCKET).

Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700.

Mittal MK, Rabinstein AA. Anticoagulation-related intracranial hemorrhages. Current Atherosclero-sis Reports. 2012;14(4):351- 359. DOI: 10.1007/s11883-012-0258-8

Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circulation Journal. 2014;44(5):281-290. DOI: 10.4070/ kcj.2014.44.5.281.

Wann LS, Alpert JS, et al, for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: 2014 Dec 2. 64 (21):e1-76. [Medline].

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146:857–867.Crossref|Medline|Google Scholar

Amin, S. Deitelzweig, Y. Jing, D. Makenbaeva, D. Wiederkehr, J. Lin, et al. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARIS-TOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis, 38 (2014), pp. 150-159

Paulus, E., Komperda, K., Park, G. et al. Anticoagulation Therapy Considerations in Factor VII Deficiency. Drug Saf - Case Rep 3, 8 (2016). https://doi.org/10.1007/s40800-016-0031-y

Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700.

Mittal MK, Rabinstein AA. Anticoagulation-related intracranial hemorrhages. Current Atherosclero-sis Reports. 2012;14(4):351- 359. DOI: 10.1007/s11883-012-0258-8

Amin, S. Deitelzweig, Y. Jing, D. Makenbaeva, D. Wiederkehr, J. Lin, et al. Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARIS-TOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis, 38 (2014), pp. 150-159

Warfarin and diet: Mayo clinic Diet http://www.mayoclinic.com/health/warfarin/AN00455. [Ac-cessed April 22, 2020].

Walfisch A, Koren G. PubMed. The "warfarin window" in pregnancy: the importance of half-life. PMID: 21176310 DOI: 10.1016/s1701-2163(16)34689-8

Krasnov G, and Kazancev I. Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy. Home > Vol 14, No 5 (2018) https://doi.org/10.20996/1819-6446-2018-14-5-687-690 [Accessed April 22, 2020].

Zareh M, Davis A, and Henderson S. Reversal of Warfarin-Induced Hemorrhage in the Emergency Department. Journal List, West J Emerg Medv.12(4); 2011 Nov, PMC3236169.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. “Dabigatran versus warfarin in patients with atrial fibrillation.” N Engl J Med 2009; 361: 1139–51. RELY

Patel M, et al. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. https://www.ncbi.nlm.nih.gov/pubmed/21830957 ROCKET Accessed April 22, 2020.

Granger CB, Alexander JH, McMurray JJ, et al. “Apixaban versus warfarin in patients with atrial fibrillation.” N Engl J Med 2011; 365: 981–92. ARISTOTLE

2019 Apr;17(4):319-330. doi: 10.1080/14779072.2019.1598263. [Epub 2019 Mar 27].

Garcia D, and Crowther M. UpToDate. Management of bleeding in patients receiving direct oral anticoagulants.

Levy JH et al. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. J Thromb Haemost 2018 Jan; 16:54. (http://dx.doi.org/10.1111/jth.13894)

Parasrampuria D and Truitt K. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. [Published online 2015 Nov 30]. doi: 10.1007/s40262-015-0342-7.

Giugliano RP, et al. ENGAGE AF-TIMI 48 Investigators. N Engl J Med. 2013 Nov 28; 369(22):2093-104.

Xarelto (rivaroxaban) tablets [package insert]. Leverkusen, Germany / Gurabo, PR: Bayer Pharma AG / Janssen Ortho, LLC. Revised: 8/2016. Available at [Full Text].

Praxbind™ (idarucizumab), A Specific Antidote for Immediate Reversal of Pradaxa® (dabigatran etexilate)1 Now Approved in Canada With Conditions. https://www.boehringer-ingelheim.ca/en/press-release/praxbind-idarucizumab-specific-antidote-immediate-reversal-pradaxa-dabigatran [Accessed April 22, 2020].

US Food and Drug Administration. FDA approves Praxbind, the first reversal agent for the antico-agulant Pradaxa [press release]. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm. October 16, 2015; [Accessed: April 5, 2020].

Sikorska J and Uprichard J. Direct Oral Anticoagulants: A Quick Guide. PMCID: PMC6206466. PMID: 30416551. doi: 10.15420/ecr.2017:11:2 [Published August 2017].

Hellenbart E, Faulkenberg K and Finks S. NCBI. Evaluation of bleeding in patients receiving direct oral anticoagulants. PMCID: PMC5574591. PMID: 28860793 2017; 13: 325–342. doi: 10.2147/VHRM.S121661 [Published August 23, 2017].

Vinogradova Y, Coupland C, Hill T, and Hippisley-Cox J. Risks and benefits of direct oral antico-agulants versus warfarin in a real world setting. BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k2505 [Published 04 July 2018].

Holy EW, Beer JH. Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Med. 2013;16:103–114. [Google Scholar] [Ref list]

BMJ : British Medical Journal. Risks and Benefits of Direct Oral Anticoagulants Versus Warfarin in a Real World Setting: Cohort Study in Primary Care. BMJ 2018 Jul 04;362(xx)k2505, Y Vinogra-dova, C Coupland, T Hill, J Hippisley-Cox. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Warfarin versus DOACs in the prevention of thromboembolic stroke in patients with Afib.